Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2013 Sep 2;202(5):779–792. doi: 10.1083/jcb.201301004

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 7. — Effects of taxol, combined taxol/Ciliobrevin-D, and low dose nocodazole on MTOC repositioning. (A) Shown are the percent contributions of the four classes of MTOC repositioning scored 10 min (left) and 30 min (right) after conjugation with +SEE Raji cells for Jurkats treated with DMSO, taxol, taxol plus Ciliobrevin-D (Taxol + Cilio D), or low dose nocodazole (LD NZ). (B) Rates of MTOC movement during the polarization and docking phases. (C) MTOC-to-IS distance 30 min after conjugation. (D) Time-lapse montage showing MTOC repositioning in a representative conjugate containing a Jurkat cell treated with DMSO (each frame is a merge of the transmitted image and the RFP-Pericentrin–labeled MTOC pseudocolored green). (E) As in D, except the Jurkat has been treated with taxol. (F) As in D, except the Jurkat has been treated with taxol and Ciliobrevin-D. The yellow lines in D–F mark the IS membrane. All data were obtained from at least three independent experiments.